Finance

Beta
Lists
4502:TYO
Takeda Pharmaceutical Co Ltd
5 359,00 JPY
-0,72%
(-39,00) 1D
10 ივლ, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4502...
Open
5 385 JPY
High
5 397 JPY
Low
5 300 JPY
Mkt. cap
8,59 ტრლ.
Avg. vol.
4,23 მლნ.
Volume
3,12 მლნ.
Dividend
3,73%
Quarterly dividend
50 JPY
Ex-dividend date
29 სექ. 2025
52-wk high
6 033 JPY
52-wk low
4 102 JPY
EPS
-97 JPY
Shares outstanding
784,48 მლნ.
No. of employees
47 ათ.
Open
5 385 JPY
High
5 397 JPY
Low
5 300 JPY
Mkt. cap
8,59 ტრლ.
Avg. vol.
4,23 მლნ.
Volume
3,12 მლნ.
Dividend
3,73%
Quarterly dividend
50 JPY
Ex-dividend date
29 სექ. 2025
52-wk high
6 033 JPY
52-wk low
4 102 JPY
EPS
-97 JPY
Shares outstanding
784,48 მლნ.
No. of employees
47 ათ.
News stories
From sources across the web
Mid Florida Newspapers
Mid Florida Newspapers
·
1 საათის წინ
Financial Markets Wall Street
CNBC
CNBC
·
19 საათის წინ
Berkshire Hathaway gains ground, but still trails the S&P 500 as '26 enters second half
Fortune
Fortune
·
23 საათის წინ
How SK Hynix just pulled off the second-largest U.S. share sale by quietly powering the AI boom
Investor's Business Daily
Investor's Business Daily
·
5 საათის წინ
Market Ready To Go? 5 Stocks Near Buy Points; Big Earnings Loom
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd
CEOკრისტოფ ვებერი | კრისტოფ ვებერი
Employees47 ათ.
Founded12 ივნ. 1781
Headquarters-
SectorPharmaceutical industry
Websitetakeda.com
Last report
13 მაი. 2026
Fiscal period
Q4 2026
EPS / Est. (JPY)
- / -
Revenue / Est. (JPY)
1,09 ტრლ. / 1,12 ტრლ.
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
ივნ. 2025
სექ. 2025
დეკ. 2025
მარ. 2026
Revenue
1,11 ტრლ.
1,11 ტრლ.
1,19 ტრლ.
1,09 ტრლ.
Cost of goods sold
384,68 მლრ.
380,06 მლრ.
401,15 მლრ.
453,33 მლრ.
Cost of revenue
384,68 მლრ.
380,06 მლრ.
401,15 მლრ.
453,33 მლრ.
Research and development expenses
143,89 მლრ.
161,48 მლრ.
175,23 მლრ.
187,96 მლრ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
255,88 მლრ.
253,55 მლრ.
282,78 მლრ.
291,96 მლრ.
Operating expense
535,14 მლრ.
562,57 მლრ.
661,30 მლრ.
519,65 მლრ.
Total operating expenses
919,82 მლრ.
942,63 მლრ.
1,06 ტრლ.
972,98 მლრ.
Operating income
186,86 მლრ.
170,17 მლრ.
129,25 მლრ.
121,56 მლრ.
Other non operating income
-77,96 მლრდ.
77,96 მლრდ.
8,80 მლრდ.
-24,50 მლრდ.
EBT including unusual items
150,63 მლრ.
28,17 მლრდ.
133,86 მლრ.
-455,02 მლრ.
EBT excluding unusual items
152,93 მლრ.
128,86 მლრ.
114,17 მლრ.
71,49 მლრდ.
Income tax expense
26,35 მლრდ.
39,90 მლრდ.
30,13 მლრდ.
-86,62 მლრდ.
Effective tax rate
17,49%
141,64%
22,51%
19,04%
Other operating expenses
6,03 მლრდ.
16,12 მლრდ.
67,13 მლრდ.
-64,27 მლრდ.
Net income
124,24 მლრ.
-11,80 მლრდ.
103,64 მლრ.
-368,47 მლრ.
Net profit margin
11,23%
-1,06%
8,70%
-33,66%
Earnings per share
-
-
-
-
Interest and investment income
73,76 მლრდ.
43,92 მლრდ.
93,00 მლრდ.
17,22 მლრდ.
Interest expense
-29,20 მლრდ.
-161,10 მლრ.
-117,68 მლრ.
-50,82 მლრდ.
Net interest expenses
44,56 მლრდ.
-117,18 მლრ.
-24,68 მლრდ.
-33,60 მლრდ.
Depreciation and amortization charges
-
-
-
-
EBITDA
368,50 მლრ.
355,15 მლრ.
182,70 მლრ.
589,63 მლრ.
Gain or loss from assets sale
-17,32 მლრდ.
303,00 მლნ.
358,00 მლნ.
1,46 მლრდ.
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer